Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document


Previous Fragment    Next Fragment

Notice given 26 September 2002

700  Senator Crossin: To ask the Minister for Family and Community Services—

(1) How many children are currently on the national waiting list for the child care Special Needs Subsidy Scheme.

(2) Where do these children live, by state and territory, and by local government area.

(3) (a) How long are children going to wait on this waiting list; and (b) is the length of time on the waiting list different in each state and territory.

(4) What is the range of special needs or disabilities these children have (can the information be broken down by category).

(5) (a) What are the details of the application process; and (b) what information is provided to parents and services regarding the new waiting list scheme.

702  Senator Lees: To ask the Minister for Health and Ageing—

(1) What was the percentage increase in Commonwealth spending on the Pharmaceutical Benefits Scheme (PBS) for each month from January to July 2002.

(2) What was the total percentage increase for the period January to July 2002.

(3) What new drugs have been listed on the PBS in the 12 months from September 2001.

(4) What is the estimated cost to the PBS of the new drugs listed in the 12 months from September 2001.

(5) What is the estimated cost of each of these newly-listed drugs.

(6) What drugs approved by the Therapeutic Goods Administration (TGA) in the past 12 months have not been listed on the PBS.

(7) Given that the diabetes drug Avandia has been approved by the TGA but has not been listed on the PBS, what impediments are preventing the listing of this particular drug.

(8) Why have the rheumatoid arthritis drugs Enbrel and Remicade , which have been approved by the TGA, not been listed.

(9) For each of the past five years (1997 to 2001 inclusive) can the following details be provided: (a) the average number of drugs listed on the PBS each year; and (b) the average number of submissions made to the Pharmaceutical Benefits Advisory Committee.

(10) What is the estimated annual cost to the PBS of the drugs approved by the TGA but still awaiting listing.